"Add-on" is scientifically more accurate than "placebo control" in multiple inflammatory bowel disease (IBD) trials.
James J. Peters Veterans Administration Medical Center, United States.
Robert John
RJ
Greenstein
Ottawa Hospital Research Institute (OHRI), Canada.
D W
DW
Cameron
James J. Peters Veterans Administration Medical Center, United States.
Sheldon T
ST
Brown
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D020022:Genetic Predisposition to Disease; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000235:genetics / Q000382:microbiology*; D019804:Mesalamine / Q000627:therapeutic use; D016927:Mycobacterium avium subsp. paratuberculosis; D010283:Paratuberculosis / Q000150:complications* / Q000188:drug therapy; D010919:Placebos; D009626:Terminology as Topic
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; D019804:Mesalamine
Anti-inflammatory; Clinical trials; Crohn's disease; Immunemodulators; Placebo; Ulcerative colitis